James R. Meyers
Independent DirectorMr. James R. Meyers, also known as Jim, serves as an Independent Director of Vera Therapeutics, Inc. since November 2025. He is Chairman of the Board of IntegriChain Incorporated. He served as President and Chief Executive Officer of IntraBio Inc since November 2020. He is a Director at Sangamo Therapeutics, Inc. since November 22, 2019 and Pulmocide Ltd. He served as an Independent Director at Arbutus Biopharma Corporation since October 18, 2018 until February 25, 2025. He joined the Arbutus Biopharma Corporation on October 18, 2018. Mr. Meyers served as an Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, Inc. from November 16, 2016 to February 2018. Mr. Meyers served as Senior Vice President of Commercial Operations - North America at Gilead Sciences, Inc. since January 25, 2007 until November 16, 2016. Mr. Meyers was responsible for Gilead's commercial organization in North America, including U.S. and Canadian sales, marketing and commercial operations, its Executive Vice President, Commercial Operations. He joined Gilead in 1996 as a Regional Sales Director and relocated to its headquarters in 1997 to head the HIV marketing team. In 2001, he was named Senior Director of U.S. Sales, overseeing the expansion of Gilead's field sales organization in advance of the launch of its first product for the treatment of HIV. He served as Vice President in 2002 and served as Vice President of the U.S. Commercial organization in 2004. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. He has been Independent Director of CytomX Therapeutics, Inc. since December 31, 2018. In addition, Mr. Meyers has served as a Senior Advisor to the Boston Consulting Group since January 2019 and the Biotechnology Innovation Organization (BIO) and has served as a Senior Advisor to Gilead Sciences, Inc. (“Gilead”) (Nasdaq: GILD) since his retirement from Gilead in February 2018. He currently serves on the board of directors of one other public biopharmaceutical company, CytomX Therapeutics, Inc. and two private biotech companies, Pumocide, Inc. and Integri Chain, a Nordic Capital Company, where he serves as Chairman of the Board. Mr. Meyers holds a B.A. in Economics from Boston University.
Positions
- Company NameCytomX Therapeutics, Inc.Stock CodeCTMXPositionIndependent DirectorColleagues
- SASean A. McCarthyChairman & CEO
- CWChristopher W. OgdenSVP, CFO & Secretary
- RLRachael LesterChief Business Officer & Senior VP
- MPMarcia P. BelvinSenior VP & Chief Scientific Officer
- AVAlejandra Veronica CarvajalChief Legal Officer
- MPMatthew P. YoungLead Independent Director
- HEHalley E. GilbertIndependent Director
- WMW. Michael KavanaughMember of Scientific Advisory Board
